摘要
目的:探讨伊沙佐米治疗难治复发多发性骨髓瘤的临床疗效及相关毒副反应。方法:2018-08-2019-08我院对15例难治复发多发性骨髓瘤患者行以伊沙佐米为基础化疗,随访分析治疗后反应率及相关毒副反应,并对相关临床指标进行分析。结果:经以伊沙佐米为基础诱导化疗诱导治疗后2例(13.3%)患者达到完全缓解,3例(20.0%)达到部分缓解,总有效率为33.3%。在治疗前,治疗无效组的血肌酐及β2微球蛋白浓度明显高于治疗有效组(均P<0.05)。伊沙佐米为基础诱导化疗常见的毒副反应包括中细粒细胞减少5例,血小板减少3例,血红蛋白下降3例,皮疹2例,肺部感染3例,肝功能异常1例,恶心5例,乏力6例。结论:伊沙佐米对部分难治复发多发性骨髓瘤安全有效,是难治复发多发性骨髓瘤的治疗新选择。
Objective:To investigate the clinical efficacy and toxicity of ixazomib in the treatment of patients with refractory or recurrent multiple myeloma.Method:From August 2018 to August 2019,15 patients with relapsed or refractory multiple myeloma were treated with ixazomib-based chemotherapy.The response rate and toxicity after treatment were followed up and analyzed,and the related clinical indicators were analyzed.Result:Two patients(13.3%)achieved complete remission and three patients(20.0%)achieved partial remission after induction chemotherapy based on ixazomib.The total effective rate was 33.3%.Before treatment,the serum creatinine and beta 2 microglobulin levels in the ineffective group were significantly higher than those in the effective group(P<0.05).The common adverse events of ixazomib based induction chemotherapy included 5 cases of granulocytopenia,3 cases of thrombocytopenia,3 cases of anemia,2 cases of skin rash,3 cases of pulmonary infection,1 case of liver dysfunction,5 cases of nausea and 6 cases of asthenia.Conclusion:Ixazomib is effective and safe for some relapsed or refractory multiple myeloma,and it is a new choice for the treatment of relapsed or refractory multiple myeloma.
作者
许晓东
曹俊杰
庄贤栩
陆滢
裴仁治
XU Xiaodong;CAO Junjie;ZHUANG Xianxu;LU Ying;PEI Renzhi(Department of Hematology,Yinzhou Hospital Affiliated to Medical School of Ningbo University,Ningbo,315000,China)
出处
《临床血液学杂志》
CAS
2020年第2期205-207,共3页
Journal of Clinical Hematology
关键词
难治复发多发性骨髓瘤
伊沙佐米
疗效
relapsed or refractory multiple myeloma
ixazomib
efficacy
